Sanofi bets big on mRNA future with Translate Bio acquisition offer
Sanofi’s CEO Paul Hudson is dead serious about mRNA technology and capabilities with a $3.2 billion acquisition offer to Translate Bio.
Moderna Vaccine Shows 94.5% Efficacy in Early Analysis
Get the latest updates and insights on COVID 19 vaccine here at the nation’s fastest-growing business magazine, Industry Leaders.
